GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Etropal AD (XBUL:ETR) » Definitions » Total Liabilities

Etropal AD (XBUL:ETR) Total Liabilities : лв10.45 Mil (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Etropal AD Total Liabilities?

Etropal AD's Total Liabilities for the quarter that ended in Dec. 2023 was лв10.45 Mil.

Etropal AD's quarterly Total Liabilities increased from Sep. 2022 (лв9.42 Mil) to Dec. 2022 (лв9.71 Mil) and increased from Dec. 2022 (лв9.71 Mil) to Dec. 2023 (лв10.45 Mil).

Etropal AD's annual Total Liabilities increased from Dec. 2021 (лв8.13 Mil) to Dec. 2022 (лв9.71 Mil) and increased from Dec. 2022 (лв9.71 Mil) to Dec. 2023 (лв10.45 Mil).


Etropal AD Total Liabilities Historical Data

The historical data trend for Etropal AD's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Etropal AD Total Liabilities Chart

Etropal AD Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.32 7.86 8.13 9.71 10.45

Etropal AD Quarterly Data
Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.80 9.47 9.42 9.71 10.45

Etropal AD Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Etropal AD's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=9.003+(1.212+4.4408920985006E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.236+0)
=10.45

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=18.562-8.111
=10.45

Etropal AD's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=9.003+(1.212+4.4408920985006E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.236+0)
=10.45

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=18.562-8.111
=10.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Etropal AD Total Liabilities Related Terms

Thank you for viewing the detailed overview of Etropal AD's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Etropal AD Business Description

Traded in Other Exchanges
N/A
Address
191 Rusky Boulevard, Etropole, Sofia, BGR, 2180
Etropal AD is engaged in the business of manufacturing medical accessories. The product portfolio includes fistula needles, blood taking sets, transfusion and infusion sets, catheters and tubes, urine collecting bags, colostomy bags, among others. The company also produces hip - joint endoprosthesis and instruments of implantation.